Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates.
Journal
The ISME journal
ISSN: 1751-7370
Titre abrégé: ISME J
Pays: England
ID NLM: 101301086
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
23
03
2018
accepted:
23
12
2018
revised:
09
10
2018
pubmed:
17
1
2019
medline:
28
10
2019
entrez:
17
1
2019
Statut:
ppublish
Résumé
Persisters are transiently antibiotic-tolerant cells that complicate the treatment of bacterial infections. Both theory and experiments have suggested that persisters facilitate genetic resistance by constituting an evolutionary reservoir of viable cells. Here, we provide evidence for a strong positive correlation between persistence and the likelihood to become genetically resistant in natural and lab strains of E. coli. This correlation can be partly attributed to the increased availability of viable cells associated with persistence. However, our data additionally show that persistence is pleiotropically linked with mutation rates. Our theoretical model further demonstrates that increased survival and mutation rates jointly affect the likelihood of evolving clinical resistance. Overall, these results suggest that the battle against antibiotic resistance will benefit from incorporating anti-persister therapies.
Identifiants
pubmed: 30647458
doi: 10.1038/s41396-019-0344-9
pii: 10.1038/s41396-019-0344-9
pmc: PMC6474225
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1251Références
Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–33.
doi: 10.1128/MMBR.00016-10
World Health Organization. Antimicrobial resistance: global report on surveillance. WHO press, Geneva, Switzerland; 2014.
Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–30.
doi: 10.1038/nrmicro.2016.34
Bumann D. Heterogeneous host-pathogen encounters: act locally, think globally. Cell Host Microbe. 2015;17:13–19.
doi: 10.1016/j.chom.2014.12.006
Conlon BP. Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells. Bioessays. 2014;36:991–6.
doi: 10.1002/bies.201400080
Michiels JE, Van den Bergh B, Verstraeten N, Michiels J. Molecular mechanisms and clinical implications of bacterial persistence. Drug Resist Updat. 2016;29:76–89.
doi: 10.1016/j.drup.2016.10.002
Van den Bergh B, Michiels JE, Fauvart M, Michiels J. Should we develop screens for multidrug tolerance? Expert Rev Anti Infect Ther. 2016;14:613–6.
doi: 10.1080/14787210.2016.1194754
Van den Bergh B, Fauvart M, Michiels J. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol Rev. 2017;41:219–51.
doi: 10.1093/femsre/fux001
Harms A, Maisonneuve E, Gerdes K. Mechanisms of bacterial persistence during stress and antibiotic exposure. Science. 2016;354:aaf4268.
doi: 10.1126/science.aaf4268
Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol. 2017;15:453–64.
doi: 10.1038/nrmicro.2017.42
Van den Bergh B, Michiels JE, Wenseleers T, Windels EM, Vanden Boer P, Kestemont D, et al. Frequency of antibiotic application drives rapid evolutionary adaptation of Escherichia coli persistence. Nat Microbiol. 2016;1:16020.
doi: 10.1038/nmicrobiol.2016.20
Michiels JE, Van den Bergh B, Verstraeten N, Fauvart M, Michiels J. In vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens. Antimicrob Agents Chemother. 2016;60:4630–7.
doi: 10.1128/AAC.00757-16
Fridman O, Goldberg A, Ronin I, Shoresh N, Balaban NQ. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature. 2014;513:418–21.
doi: 10.1038/nature13469
Mechler L, Herbig A, Paprotka K, Fraunholz M, Nieselt K, Bertram R. A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59:5366–76.
doi: 10.1128/AAC.00643-15
Moreillon P, Tomasz A. Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment. J Infect Dis. 1988;157:1150–7.
doi: 10.1093/infdis/157.6.1150
Levin BR, Rozen DE. Non-inherited antibiotic resistance. Nat Rev Microbiol. 2006;4:556–62.
doi: 10.1038/nrmicro1445
Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug resistance. Cell Host Microbe. 2013;13:632–42.
doi: 10.1016/j.chom.2013.05.009
Liu HH, Tomasz A. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J Infect Dis. 1985;152:365–72.
doi: 10.1093/infdis/152.2.365
Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature. 1999;399:590–3.
doi: 10.1038/21202
Sebastian J, Swaminath S, Nair RR, Jakkala K, Pradhan A, Ajitkumar P. De novo emergence of genetically resistant mutants of Mycobacterium tuberculosis from the persistence phase cells formed against antituberculosis drugs in vitro. Antimicrob Agents Chemother. 2016;61:AAC.01343-16.
doi: 10.1128/AAC.01343-16
Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017;355:826–30.
doi: 10.1126/science.aaj2191
Vogwill T, Comfort AC, Furió V, MacLean RC. Persistence and resistance as complementary bacterial adaptations to antibiotics. J Evol Biol. 2016;29:1223–33.
doi: 10.1111/jeb.12864
Bjedov I, Tenaillon O, Gérard B, Souza V, Denamur E, Radman M, et al. Stress-induced mutagenesis in bacteria. Science. 2003;300:1404–9.
doi: 10.1126/science.1082240
Al Mamun, AAM Lombardo M, Shee C, Lisewski AM, Gonzalez C, et al. Identity and function of a large gene network underlying mutagenic repair of DNA breaks. Science. 2012;338:1344–8.
doi: 10.1126/science.1226683
Poole K. Stress responses as determinants of antimicrobial resistance in Gram-negative bacteria. Trends Microbiol. 2012;20:227–34.
doi: 10.1016/j.tim.2012.02.004
Kussell E, Kishony R, Balaban NQ, Leibler S. Bacterial persistence: a model of survival in changing environments. Genetics. 2005;169:1807–14.
doi: 10.1534/genetics.104.035352
Carja O, Liberman U, Feldman MW. Evolution in changing environments: Modifiers of mutation, recombination, and migration. Proc Natl Acad Sci. 2014;111:17935–40.
doi: 10.1073/pnas.1417664111
Ishii K, Matsuda H, Iwasa Y, Sasaki A. Evolutionarily stable mutation rate in a periodically changing environment. Genetics. 1989;121:163–74.
pubmed: 17246489
pmcid: 1203599
Swings T, Van den Bergh B, Wuyts S, Oeyen E, Voordeckers K, Verstrepen KJ, et al. Adaptive tuning of mutation rates allows fast response to lethal stress in Escherichia coli. eLife. 2017;6:1–24.
doi: 10.7554/eLife.22939
Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother. 2002;46:863–5.
doi: 10.1128/AAC.46.3.863-865.2002
Giraud A, Matic I, Tenaillon O, Clara A, Radman M, Fons M, et al. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science. 2001;291:2606–8.
doi: 10.1126/science.1056421
Ram Y, Hadany L. The evolution of stress-induced hypermutation in asexual populations. Evolution. 2012;66:2315–28.
doi: 10.1111/j.1558-5646.2012.01576.x
Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ. Nongenetic individuality in the host-phage interaction. PLoS Biol 2008;6:0957–64.
doi: 10.1371/journal.pbio.0060120
Wang H, Dzink-Fox J, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother. 2001;45:1515–21.
doi: 10.1128/AAC.45.5.1515-1521.2001
Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother. 2004;48:3670–6.
doi: 10.1128/AAC.48.10.3670-3676.2004
Stepanyan K, Wenseleers T, Duéñez-Guzmán EA, Muratori F, Van den Bergh B, Verstraeten N, et al. Fitness trade-offs explain low levels of persister cells in the opportunistic pathogen Pseudomonas aeruginosa. Mol Ecol. 2015;24:1572–83.
doi: 10.1111/mec.13127
Sahl JW, Matalka MN, Rasko DA. Phylomark, a tool to identify conserved phylogenetic markers from whole-genome alignments. Appl Environ Microbiol. 2012;78:4884–92.
doi: 10.1128/AEM.00929-12
Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95–98.
Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.
doi: 10.1093/molbev/msm092
Hamon A, Ycart B. Statistics for the Luria-Delbrück distribution. Electron J Stat. 2012;6:1251–72.
doi: 10.1214/12-EJS711
Ycart B, Veziris N. Unbiased estimation of mutation rates under fluctuating final counts. PLoS ONE. 2014;9:e101434.
doi: 10.1371/journal.pone.0101434
Mazoyer A, Drouilhet R, Despréaux S, Ycart B. flan: An R package for inference on mutation models. R J. 2017;9:334–51.
doi: 10.32614/RJ-2017-029
Stewart FM. Fluctuation analysis: the effect of plating efficiency. Genetica. 1991;84:51–55.
doi: 10.1007/BF00123984
Ochman H, Selander RK. Standard reference strains of Escherichia coli from natural populations. J Bacteriol. 1984;157:690–3.
pubmed: 6363394
pmcid: 215307
Stewart B, Rozen DE. Genetic variation for antibiotic persistence in Escherichia coli. Evolution. 2011;66:933–9.
doi: 10.1111/j.1558-5646.2011.01467.x
Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 2005;3:1024–33.
doi: 10.1371/journal.pbio.0030176
Riesenfeld C, Everett M, Piddock LJ, Hall BG. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother. 1997;41:2059–60.
doi: 10.1128/AAC.41.9.2059
Alam MK, Alhhazmi A, DeCoteau JF, Luo Y, Geyer CR. RecA inhibitors potentiate antibiotic activity and block evolution of antibiotic resistance. Cell Chem Biol. 2016;23:381–91.
doi: 10.1016/j.chembiol.2016.02.010
Kaspy I, Rotem E, Weiss N, Ronin I, Balaban NQ, Glaser G. HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. Nat Commun. 2013;4:3001.
doi: 10.1038/ncomms4001
Germain E, Castro-Roa D, Zenkin N, Gerdes K. Molecular mechanism of bacterial persistence by HipA. Mol Cell. 2013;52:248–54.
doi: 10.1016/j.molcel.2013.08.045
Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature. 2011;473:216–20.
doi: 10.1038/nature10069
Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999;58:11–18.
doi: 10.2165/00003495-199958002-00003
Oz T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol. 2014;31:2387–401.
doi: 10.1093/molbev/msu191
Lázár V, Nagy I, Spohn R, Csörgő B, Györkei Á, Nyerges Á, et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nat Commun. 2014;5:4352.
doi: 10.1038/ncomms5352
Conrad S, Oethinger M, Kaifel K, Klotz G, Marre R, Kern WV. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother. 1996;38:443–55.
doi: 10.1093/jac/38.3.443
Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother. 1998;42:2661–7.
doi: 10.1128/AAC.42.10.2661
Ankomah P, Levin BR. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proc Natl Acad Sci USA. 2014;111:8331–8.
doi: 10.1073/pnas.1400352111
Putrinš M, Kogermann K, Lukk E, Lippus M, Varik V, Tenson T. Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement. Infect Immun. 2015;83:1056–67.
doi: 10.1128/IAI.02725-14
Levin BR, Baquero F, Ankomah P, McCall IC. Phagocytes, antibiotics, and self-limiting bacterial infections. Trends Microbiol. 2017;25:878–92.
doi: 10.1016/j.tim.2017.07.005
Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002;252:91–106.
doi: 10.1046/j.1365-2796.2002.01026.x
Yaakov G, Lerner D, Bentele K, Steinberger J, Barkai N. Coupling phenotypic persistence to DNA damage increases genetic diversity in severe stress. Nat Ecol Evol. 2017;1:16.
doi: 10.1038/s41559-016-0016
Kussell E, Leibler S. Phenotypic diversity, population growth, and information in fluctuating environments. Science. 2005;309:2075–8.
doi: 10.1126/science.1114383
Patra P, Klumpp S. Population dynamics of bacterial persistence. PLoS ONE. 2013;8:e62814.
doi: 10.1371/journal.pone.0062814
Gardner A, West SA, Griffin AS. Is bacterial persistence a social trait? PLoS ONE. 2007;2:e752.
doi: 10.1371/journal.pone.0000752
Méhi O, Bogos B, Csörgo B, Pál C. Genomewide screen for modulators of evolvability under toxic antibiotic exposure. Antimicrob Agents Chemother. 2013;57:3453–6.
doi: 10.1128/AAC.02454-12
Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37:311–20.
doi: 10.1016/j.molcel.2010.01.003
Long H, Miller SF, Strauss C, Zhao C, Cheng L, Ye Z, et al. Antibiotic treatment enhances the genome-wide mutation rate of target cells. Proc Natl Acad Sci USA. 2016;113:E2498–E2505.
doi: 10.1073/pnas.1601208113
LaFleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother. 2010;54:39–44.
doi: 10.1128/AAC.00860-09
Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010;192:6191–9.
doi: 10.1128/JB.01651-09
Bridges BA. DNA turnover and mutation in resting cells. Bioessays. 1997;19:347–52.
doi: 10.1002/bies.950190412
Williams AB, Foster PL. Stress-induced mutagenesis. EcoSal Plus. 2012;5:1–29.
doi: 10.1128/ecosalplus.7.2.3
Roth JR, Kugelberg E, Reams AB, Kofoid E, Andersson DI. Origin of mutations under selection: the adaptive mutation controversy. Annu Rev Microbiol. 2006;60:477–501.
doi: 10.1146/annurev.micro.60.080805.142045
Rosenberg SM, Shee C, Frisch RL, Hastings PJ. Stress-induced mutation via DNA breaks in Escherichia coli: A molecular mechanism with implications for evolution and medicine. Bioessays. 2012;34:885–92.
doi: 10.1002/bies.201200050
O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. 2014.
Rosenberg SM, Queitsch C. Combating evolution to fight disease. Science. 2014;343:1088–9.
doi: 10.1126/science.1247472
Cirz RT, Romesberg FE. Controlling mutation: intervening in evolution as a therapeutic strategy. Crit Rev Biochem Mol Biol. 2007;42:341–54.
doi: 10.1080/10409230701597741
Goldberg DE, Siliciano RF, Jacobs WR. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell. 2012;148:1271–83.
doi: 10.1016/j.cell.2012.02.021
Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol. 2011;14:519–23.
doi: 10.1016/j.mib.2011.08.003
Imamovic L, Sommer MOA. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013;5:204ra132.
doi: 10.1126/scitranslmed.3006609
Oxnard GR. The cellular origins of drug resistance in cancer. Nat Med. 2016;22:232–4.
doi: 10.1038/nm.4058
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247–50.
doi: 10.1038/nature24297